Daratumumab Combination Lengthened PFS for Heavily Pretreated Myeloma

Adding the CD38-targeting monoclonal antibody daratumumab to bortezomib and dexamethasone resulted in significantly improved progression-free survival in patients with heavily pretreated multiple myeloma.

Source: CancerNetwork - September 1, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news